Incidence of metachronous visible lesions in patients referred for radiofrequency ablation (RFA) therapy for early Barrett’s neoplasia: a single-centre experience

J Ortiz-Fernández-Sordo,1 S Sami,1 R Mansilla-Vivar,1 J De Caestecker,2 A Cole,3 K Ragunath1

1Nottingham Digestive Diseases Centre and NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK
2Digestive Diseases Centre, University Hospitals of Leicester NHS Trust, Leicester, UK
3Gastroenterology and Hepatology Department, Derby Hospitals NHS Foundation Trust, Derby, UK

Correspondence to
Professor Krish Ragunath MD FRCP FASGE, Professor & Head of GI Endoscopy, Nottingham Digestive Diseases Centre, NIHR Biomedical Research Unit, Queens Medical Centre campus, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK; K.Ragunath@nottingham.ac.uk

Received 7 January 2015
Revised 5 February 2015
Accepted 9 February 2015
Published Online First 13 March 2015


ABSTRACT

Objective Evaluate the incidence of metachronous visible lesions (VLs) in patients referred for radiofrequency ablation (RFA) for early Barrett’s neoplasia.

Design This study was conducted as part of the service evaluation audit.

Setting Tertiary referral centre.

Patients All patients with dysplastic Barrett’s oesophagus referred for RFA were included for analysis. White light high-resolution endoscopy (HRE), autofluorescence imaging and narrow band imaging were sequentially performed. Endoscopic mucosal resection (EMR) was performed for all VL. Three to six months after EMR, all patients underwent initial RFA and then repeat RFA procedures at three monthly intervals.

Interventions All endoscopy reports and final staging by EMR/surgery were evaluated and included for analysis.

Results Fifty patients were analysed; median age 73 years, 84% men. 38/50 patients (76%) had a previous EMR due to the presence of VL before referred for ablation; twelve patients had no previous treatment. In total, 151 ablation procedures were performed, median per patient 2.68. Twenty metachronous VL were identified in 14 patients before the first ablation or during the RFA protocol; incidence was 28%. All metachronous lesions were successfully resected by EMR. Upstaging after rescue EMR compared with the initial histology was observed in four patients (28%).

Conclusions In total, 28% of patients enrolled in the RFA programme were diagnosed to have metachronous lesions. This high-incidence rate highlights the importance of a meticulous examination to identify and resect any VL before every ablation session. RFA treatment for early Barrett’s neoplasia should be performed in tertiary referral centres with HRE and EMR facilities and expertise.

INTRODUCTION

Barrett’s oesophagus (BO) with high-grade dysplasia (HGD) is the most important risk factor for developing oesophageal adenocarcinoma, the most rapidly increasing cancer in western countries. The global incidence of oesophageal cancer arising from BO is 0.5% per year1 2 and increases up to 10% yearly in patients with BO and HGD.3

In BO, the normal squamous mucosa is replaced by columnar epithelium with the presence of intestinal metaplasia (IM). The malignant transformation of BO from non-dysplastic IM to invasive adenocarcinoma is a gradual process through well-known sequential histological stages: low-grade dysplasia (LGD), HGD and early intramucosal cancer (IMC/T1a).

All these early lesions have a negligible risk of lymph node metastases, which is clearly related to the depth of tumour infiltration in the oesophageal wall.4 5 The incidence of lymph node metastases is between 0% and 3% for lesions limited to the mucosa (T1a/m1–m3), but rises up to 30% when the lesion is invading the submucosal (SM) layer (T1b/sm1–sm3).6 7
Despite the lack of randomised controlled trials and cost-effectiveness analysis, endoscopic surveillance programmes with targeted biopsies from any visible lesion (VL) and random four-quadratic biopsies have been shown to detect the presence of neoplasia at a potentially curative stage. Most of the current clinical guidelines developed by gastrointestinal societies recommend regular endoscopic surveillance for Barrett’s patients to detect neoplastic lesions in an early stage.

These early neoplastic lesions are difficult to identify with conventional white light endoscopy and other diagnostic tools, such as endoscopic ultrasound, have shown to have virtually no clinical impact on the workup of early oesophageal neoplasia because its lack of accuracy to differentiate between mucosal and sub-mucosal invasive cancer. Up to 25% of 0-Ia and 0-Iic lesions may harbour SM invasion.

To ensure cancers are not inadvertently ablated, a baseline HRE should be performed in all Barrett’s patients with HGD before ablation therapy to detect any VL suitable for endoscopic resection.

The incidence of metachronous VL in patients referred for treatment with RFA for dysplastic BO and its impact in the treatment outcomes has not been well established.

**AIMS**

To evaluate the incidence of metachronous VLs in patients referred for RFA therapy for early Barrett’s neoplasia.

**PATIENTS AND METHODS**

All patients with dysplastic BO referred for endoscopic treatment with RFA to our institution were prospectively collected and included for analysis (June 2012 to December 2014). This study was conducted as part of the service evaluation audit; hence, formal ethics application was not required.

Before any ablation treatment, a careful endoscopic examination with white light HRE and AFI followed by NBI was sequentially performed (GIF-FQ260Z, Olympus Optical, Tokyo, Japan) in all patients by an expert endoscopist (KR, JDC, AC). Endoscopic characteristics of the Barrett’s segment according to the Prague classification and endoscopic appearances of all VLs according to the Paris classification were recorded per procedure and patient.

EMR was performed for all identified VL using the multiband technique (Duette; Cook Endoscopy, Limerick, Ireland) or the cap-assisted technique (Olympus, Tokyo, Japan). Three to six months after the initial EMR, all patients were treated with RFA either with HALO, HALO 90, HALO 60, HALO Ultra or HALO TTS systems (Covidien, Dublin, Ireland). Ablation with argon plasma coagulation (APC) (ERBE Elektromedizin GmbH, Tübingen, Germany) was also used for residual ultrashort Barrett’s segments or small islands after RFA and was also considered as an ablation procedure. Repeat ablation sessions were performed at 3-month intervals.

Metachronous lesions during RFA were defined as any VL within the Barrett’s segment identified at the first visit for RFA treatment or at any scheduled visit for ablation during the RFA treatment protocol. Endoscopic characteristics according to the Paris classification were recorded. EMR was performed using the same technique described above for all metachronous lesions and final histology was included for analysis.

All endoscopy reports, final histology and staging by EMR/surgery were evaluated and included for analysis.
RESULTS
A total of 50 patients with dysplastic BO referred for RFA and enrolled in the ablation treatment protocol were analysed; median age was 73 years, range 46–83, and 84% were men. The median length of BO was 6 cm (range 1–16 cm).

Initial histology from previous mapping and/or target biopsies was LGD in two patients, HGD in 34, IMC in 13 and SM cancer in one patient. The only patient with SM cancer was referred for surgery and underwent RFA treatment for residual BO after oesophagectomy. Baseline and demographic characteristics are summarised in table 1.

Thirty-eight of 50 patients (76%) had a previous EMR due to the presence of VLs before referred for ablation. Twelve patients had a flat Barrett’s segment with no previous treatment.

A total of 151 ablation procedures were performed, median per patient 2.68, range 1–6 sessions. RFA was successfully applied in 139 sessions (HALO$^{360}$=29, HALO$^{60}$=74, HALO$^{60}$=9, HALO Ultra=15 and HALO TTS=12). APC was used as a rescue ablation method in 12 patients at the end of the treatment protocol. All of them had a single session with APC and it was their last interventional endoscopy.

Twenty of the 50 patients (40%) who entered the ablation protocol finished the treatment and are on endoscopic surveillance; no evidence of residual or recurrent dysplasia was noted on biopsies follow-up.

A total of 20 metachronous lesions were identified in 14 patients at the first RFA visit or during the ablation treatment; incidence was 28%. Two patients had two different VLs, one patient had three VLs and two patients had a VL in two different ablation visits. Endoscopic characteristics according to the Paris classification were 0–Is=1, 0–IIa=18 and 0–IIb=1.

All metachronous lesions were successfully resected by EMR; final histology per lesion was non-dysplastic BO in 1, LGD in 1, HGD in 11, IMC in 5 and SM cancer in 2 lesions. Both patients with SM invasion on the rescue EMR specimen had T1sm2 tumours. One was not candidate for surgery and re-entered the RFA treatment due to residual dysplastic BO during the follow-up; the other patient was referred for surgery.

Upstaging after rescue EMR compared with the initial histology was observed in four patients (28%), histological assessment of EMR specimens showed SM invasion in 2.

Time of diagnosis of metachronous lesions is shown in table 2; median ablation visit 1.5, mean 2.5. Combined EMR and RFA on the same session were successfully performed in five patients with metachronous lesions (figures 1 and 2).

DISCUSSION
Combined endoscopic treatment with EMR of any macroscopic lesion followed by complete eradication of the residual Barrett’s segment with RFA has become the treatment of choice for early Barrett’s neoplasia. The aim of the endoscopic therapy is the eradication of the whole Barrett’s segment due to the high risk of synchronous and metachronous lesions. Many clinical trials from Europe and the USA,$^{18-22,24-26}$ data from the UK Halo RFA Registry,$^{10}$ and a recently published meta-analysis$^{17}$ have shown excellent rates of complete eradication of dysplasia and IM with very low recurrence rates up to 5 years of follow-up.

There are no published studies clearly focused on metachronous or recurrent macroscopic lesions during the ablation treatment. Several studies conducted by the Amsterdam group showed incidence rates of metachronous lesions during treatment or follow-up period between 4% and 9%. Most recently, data from the UK Halo RFA Registry, including a total of 335 patients, reported an incidence of metachronous lesions during RFA treatment protocol of 10%.$^{10}$

Our study has showed that up to 28% of patients enrolled in an RFA programme were diagnosed to

Table 1  Demographics and Barrett’s segment characteristics

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>50</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>73.5 (range 46–83)</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>42/8</td>
</tr>
<tr>
<td>Barrett’s type</td>
<td></td>
</tr>
<tr>
<td>Short segment</td>
<td>4 (8%)</td>
</tr>
<tr>
<td>Long segment</td>
<td>46 (92%)</td>
</tr>
<tr>
<td>Median Barrett’s length (cm)</td>
<td>6 (range 1–16)</td>
</tr>
<tr>
<td>Visible lesions before RFA</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>12 (24%)</td>
</tr>
<tr>
<td>No</td>
<td>38 (76%)</td>
</tr>
<tr>
<td>Initial histological diagnosis</td>
<td></td>
</tr>
<tr>
<td>LGD</td>
<td>2</td>
</tr>
<tr>
<td>HGD</td>
<td>34</td>
</tr>
<tr>
<td>IMC</td>
<td>13</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>RFA</td>
<td>11</td>
</tr>
<tr>
<td>EMR+RFA</td>
<td>38</td>
</tr>
<tr>
<td>Surgery+RFA</td>
<td>1</td>
</tr>
</tbody>
</table>

EMR, endoscopic mucosal resection; HGD, high-grade dysplasia; IMC, intramucosal cancer; LGD, low-grade dysplasia; RFA, radiofrequency ablation.

Table 2  Time of diagnosis of metachronous lesions (n=16)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ablation visit 1</td>
<td>6 (37.5%)</td>
</tr>
<tr>
<td>Ablation visit 2</td>
<td>3 (18.7%)</td>
</tr>
<tr>
<td>Ablation visit 3</td>
<td>4 (25%)</td>
</tr>
<tr>
<td>Ablation visit 4</td>
<td>3 (18.7%)</td>
</tr>
<tr>
<td>Ablation visit 5</td>
<td>0</td>
</tr>
<tr>
<td>Ablation visit 6</td>
<td>0</td>
</tr>
</tbody>
</table>
have metachronous lesions within the Barrett’s segment at their first visit for RFA or during the treatment period. The diagnosis of new VL during RFA treatment had a big impact in the therapeutic management of two patients who had SM invasion in the rescue EMR specimens.

Figure 1  O–Ila metachronous lesion resected by endoscopic mucosal resection (IMC/T1a). Radiofrequency ablation HALO360 performed on the same session.

Figure 2  O–Ilb metachronous lesion resected by endoscopic mucosal resection (IMC/T1a). Radiofrequency ablation HALO90 performed on the same session.
Main limitation of our study is that this is a single-centre experience and shows data from a small case series. This high-incidence rate highlights the importance of a meticulous examination to identify and resect any superficial lesion before every ablation session to avoid ablation of deep invasive cancer.

Treatment with RFA for early Barrett’s neoplasia should be performed in tertiary referral centres by expert endoscopists with an adequate training in advanced endoscopic imaging and EMR facilities and expertise.

Key messages

What is already known on this topic

- EMR of any macroscopic focal lesion followed by eradication of all residual Barrett’s segment with RFA has become the treatment of choice for HGD and mucosal cancer in Barrett’s oesophagus.

What this study adds

- We found a high incidence of metachronous visible lesions in patients referred for RFA or in patients undergoing ablation therapy.

How might it impact on clinical practice in the foreseeable future

- Meticulous examination to identify and resect any superficial lesion before every ablation session is mandatory. RFA for early Barrett’s neoplasia should be performed in tertiary referral centres by expert endoscopists with an adequate training in advanced endoscopic imaging and EMR facilities and expertise.

Contributors

JO-F-S and KR: Involved in substantial contributions to manuscript concept and design. JO-F-S: Performed data collection, analysis and interpretation. All authors participated in drafting the article, revising and approval of content for final version.

Competing interests

KR has received research support, educational grants, speaker honoraria, and consultancy fees from Olympus Keymed, Pentax, Cook Medical, Cividien and Boston Scientific.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


